We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Trial to evaluate the safety and tolerability of the Farnesoid X Receptor (FXR) agonist TERN-101 to support its clinical trials for the treatment of nonalcoholic steatohepatitis (NASH)
Terns Pharmaceuticals announced the initiation of a Phase 1 clinical trial of TERN-101, a farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepatitis (NASH).
Terns Pharmaceuticals announced the appointment of Erin Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk brings more than two decades of clinical medicine and drug development experience....